This advisory is consistent with our analysis and recommendations in the third edition of Topics in Food and Drug Law: How to Comply with Drug CGMPs, our reference guide on the compliance standards and governing principles for current good manufacturing practices, tailored for members of the legal community and regulated industry.
The Food and Drug Administration's (FDA) draft guidance published on March 6, 2026, Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection, is the FDA’s first draft guidance issued to drug manufacturers on crafting effective responses to FDA Form 483 observations. It applies to foreign and domestic human and animal drug manufacturers inspected by the FDA and regulated by the Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, or Center for Veterinary Medicine.
The Importance of a FDA Form 483 – and a Firm’s Response
Under Section 704(a)(1) of the Federal Food, Drug, and Cosmetic Act (FDCA), investigators are authorized to collect and review documentation and other evidence during establishment inspections to assess compliance with current good manufacturing practice (CGMP) requirements. Finished drug products and active pharmaceutical ingredients are considered adulterated if they do not comply with the requirements set forth in 21 C.F.R. Parts 210 and 211 (and Part 212 for PET drugs). The requirements for active pharmaceutical ingredients (APIs) are statutory, so for API manufacturers, the FDA has issued guidance that is consistent with the FDA regulations in “Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients.” The FDCA also provides that introducing an adulterated drug into interstate commerce is a prohibited act.
A 483, issued at the conclusion of an inspection, notifies a firm’s management of objectionable conditions observed during the inspection. Observations appearing on a 483 are issued when, in the investigator’s judgment, the conditions or practices observed indicate that a drug product has been adulterated or is being prepared, packed, or held under conditions that may cause it to become adulterated or rendered injurious to health.
According to the draft guidance, responding to a 483 gives a firm an opportunity to clearly explain how it has addressed the FDA's concerns. While preparing a response to a 483 could appear to be a routine administrative task, as explained in the background section of its Federal Register notice, the FDA issued this draft guidance after receiving many inadequate, poor quality, and incomplete 483 responses.
After a firm submits its response to the 483, the FDA determines whether the firm has achieved voluntary compliance or that official action is indicated if the objectionable conditions are not remediated. An inadequate 483 response can therefore lead to regulatory actions, such as the FDA’s refusal to approve pending applications, warning letters, and import alerts. Moreover, a firm that consistently submits inadequate responses could face potential enforcement action, including civil and criminal prosecution.
Understanding and Assessing Observation Severity
Following the receipt of a 483, the “15 working day” clock starts and firms are encouraged to prepare written responses demonstrating that they have taken the time to develop a clear understanding of the FDA’s observations and a plan to properly address them.
The FDA’s Investigations Operations Manual (IOM) instructs investigators to make “every reasonable effort” to notify establishments of observations on a daily basis during an inspection to avoid misunderstandings or surprises at the conclusion of the inspection. Consistent with these instructions, the draft guidance encourages establishment management to engage with FDA investigators to obtain any needed clarification about their observations. The close-out meeting is a second opportunity for establishment management to ask investigators for clarification. If investigators are reluctant to provide clarity, establishments should refer the investigators to the IOM and the new draft guidance.
Firms should also consider whether the observations could be part of a systemic concern at the site or across the manufacturing network. A key concern is the potential impact of an observation on patient safety and product quality, so understanding each observation’s scope is essential—even if the observation does not identify specific products or batches that the investigator believes to be at risk.
Consider, for example, the following:
- A firm should determine whether a field alert report is warranted. Under 21 C.F.R. Section 314.81, these reports must be filed within three working days of the firm’s becoming aware of specific risks associated with a distributed product.
- Observations that reference dirty or contaminated equipment may require an establishment to take immediate action, including sampling and analysis of residue on equipment.
- The draft guidance recommends employee interviews as a component of an investigation. Those should occur promptly and be documented.
Management’s Role
One of the most important elements of CGMP compliance is management oversight and responsibility. Footnote 12 of the draft guidance refers to ICH Q10, which augments CGMPs by describing management responsibilities as critical quality system elements. While ICH Q10 defines the roles of “senior management,” the draft guidance draws a distinction between “establishment management” and “executive management” and clarifies the agency’s expectations for both.
The draft guidance describes establishment management's role in providing the site leadership necessary for the successful functioning of a site's quality system. The draft guidance recognizes that establishment management can evaluate issues, provide management oversight at the site level, and consider whether adequate resources have been committed to addressing the FDA's observations, but it describes executive management as having the authority to allocate resources and implement commitments.
The FDA’s expectations of executive management are evident in its warning letters, which often include language about inadequate management oversight. The draft guidance reminds executive management at an earlier stage of the inspection process that executive management remains responsible for resolving all deficiencies and ensuring ongoing CGMP compliance.
Responding to the 483 Observations
There are significant legal risks associated with submitting inadequate responses. There are also financial risks. A strong response might satisfy the FDA’s concerns that an establishment is in compliance with CGMP requirements or is capable of voluntarily addressing problems when they arise. An inadequate response will inevitably result in an official action indicated (OAI) inspection classification, could lead to a warning letter, and may prompt the FDA to consider use of enforcement tools.
A cycle of increased regulatory scrutiny can be far more expensive than investing time and resources in compliance before an inspection and in developing a strong initial 483 response after one. The FDA’s draft guidance should be considered in this context, and it is in the firm’s best interest to follow, as much as practicable, the draft guidance’s substantive suggestions, as well as those related to response format, developing an executive summary, and providing interim reports about ongoing actions.
Response format and content
The FDA recommends that the 483 responses be well organized and comprehensive to ensure that all relevant information is effectively captured. Although the FDA’s receipt of poor quality and inadequate 483 responses led the agency to issue this draft guidance, it is important to note that the FDA considers responses to be inadequate not only because of “a lack or omission of relevant data” but also because of “excessive amounts of data.” Firms must strike the right balance and provide evidence that is responsive to each observation.
Although the FDA states in the draft guidance that responding to a 483 is “voluntary,” issuance of the guidance means that responding to a 483 is an agency expectation. In practice, the only optional decision is whether to provide responses to the FDA’s verbal discussion items in addition to the written observations. FDA investigators note their discussion items in the establishment inspection report, so it is likely that these issues will be covered in the next inspection. Addressing discussion items in the initial response can reduce the likelihood of an untitled letter or an observation during the next inspection.
The FDA is asking establishments to identify, in a clear and organized manner, who is responsible for the response, who is assisting with the response, and what information supports the establishment’s remediation commitments—in the form of final, signed evidentiary attachments. These recommendations should be understood as substantive, not merely administrative.
By recommending that the response be signed by a person who allocates resources and has authority to implement commitments, the FDA is signaling that it expects executive management to be accountable and not leave the responsibilities for site remediation solely to site-level quality personnel or the head of the quality unit.
The FDA’s request that the establishment identify the response preparer, including any consultants or outside counsel, allows the FDA to assess compliance with 21 C.F.R. Section 211.34 by reviewing the qualifications of those supporting the establishment’s corrective actions and provides insight into the level of resources being committed to remediation. The FDA requests a letter of authorization for any third party retained to assist the establishment with remediation activities. The FDA requires letters of authorization for third parties that interact directly with the FDA or make submissions to the FDA’s electronic databases on the establishment’s behalf.
In the draft guidance, the FDA encourages the use of a multidisciplinary investigation team, which typically should include subject-matter experts from quality and operations, when responding to 483 observations. This team should have a clear line of communication with both tiers of management to ensure executive management is frequently updated and able to dedicate the resources necessary to the multidisciplinary team.
The draft guidance explains that the FDA expects firms to take the following actions and describe them in the 483 response:
- Perform Risk Assessments. The FDA's draft guidance aligns with ICH Q9 (R1), which defines a risk assessment as a “systematic process of organizing information to support a risk decision to be made within a risk management process. It consists of the identification of hazards and the analysis and evaluation of risks associated with exposure to those hazards.” Conducting an adequate risk assessment is a critical component of a response and a core competency that should exist at the site level. Based on risk assessments, establishments should take appropriate actions, such as immediate actions, interim controls, performing additional investigations to understand the scope of the issue, or implementing appropriate corrective action and preventive actions (CAPAs).
- Implement Interim Controls. Although the draft guidance does not provide any meaningful detail on this topic, there are repeated references to interim actions, or interim measures, which the FDA expects a firm to consider and implement as a short-term measure until CAPAs are completed.
- Conduct Thorough Investigations. Under 21 C.F.R. Section 211.192, establishments are required to investigate “any unexplained discrepancy … or the failure of a batch or any of its components to meet any of its specifications.” The FDA expects:
- A written investigation plan, including a detailed methodology for the investigation.
- A scientifically justified investigation scope.
- Updated risk assessments based on inspection findings, including, if warranted, an extension of the investigation to other batches or other products as required by 21 C.F.R. Section 211.192.
- Rigorous root cause analysis, not simply action to address the most obvious causal factors, including assessing why the quality unit did not identify the relevant issues before the FDA’s observation.
- A documented investigation report with well-founded conclusions or the need for follow-up.
- Review Systemic Issues. The guidance suggests that establishments explain how they have assessed for systemic concerns. If an establishment identifies any repeat observations or trends, it should determine appropriate corrective and preventive actions, including those that are relevant for the quality system or network, and discuss those actions in the response. To evaluate whether there are systemic issues at the site or within the manufacturing network, firms should consider grouping observations, for example by failure mode, department, or quality system. Firms should also review trend analyses, previous inspection findings, and internal/external audits for similar observations or repeat concerns, even if the FDA has not labeled them as repeat observations in the current 483.
- Design and Implement CAPAs. In addition to the investigation plan, the FDA recommends the development of a CAPA plan. CAPAs should be commensurate with the risk of the observation, and they should be designed to address the root causes identified during an investigation. The FDA also recommends developing a “communication plan” as part of the CAPA plan, including clear steps for completion, timelines, and deliverables.
- Include CAPA Effectiveness Measures. The FDA also expects firms to commit to assessing CAPA effectiveness. In the draft guidance, the FDA refers to the plan-do-check-act (PDCA) cycle of a quality system detailed in ICH Q10 as a useful consideration for assessing CAPA effectiveness. The FDA also recommends use of a monitoring system to track CAPA effectiveness and identify any need for improvement to investigation and CAPA systems. If monitoring shows that there are challenges with CAPA effectiveness, the establishment should investigate why this is an issue.
- Commit to Ongoing Communication. The FDA’s guidance recommends that firms develop a formal communication plan for ongoing remediation activities, including key deliverables and details on when and how updates will be submitted. This suggests that the agency is looking beyond the initial response to understand the firm’s overall remediation strategy and to obtain evidence of continued progress.
- Draft an Executive Summary. In a 483 response, the executive summary appears at the front of the document, but as a practical matter, it should be one of the final—and most important—sections that a firm drafts. The executive summary includes a strategic mix of scientific, technical, and regulatory knowledge, and it serves as an opportunity for firms to summarize the key actions they are taking to address the FDA's observations and make improvements to its systems and greater network. The FDA's draft guidance states that the executive summary should be a summary of all remediation activities and highlight "key details." This suggests a need for significant planning and analysis before drafting the response to understand how the FDA’s observations—and the actions needed to address them—are connected. Simply responding to the specific events described in an observation will not be sufficient.
Scientific or Technical Disagreements with the FDA’s Observations
The draft guidance concludes with a very short discussion in Section V acknowledging that scientific and technical issues may arise during an inspection. Although the FDA encourages firms to describe the contested facts and provide supporting information, little guidance is provided on how to do so in a careful and considered manner. Since an observation appearing in a 483 reflects only “the investigator’s judgment,” firms must carefully consider how best to challenge that judgment, and whether other reviewers within the agency may perceive this information differently.
Whether the result of a misunderstanding or passionate debate, firms should consider the value of an independent subject-matter expert to help resolve any significant scientific or technical disagreement. When it becomes necessary to review, analyze, and discuss applicable FDA statutes, regulations, or guidance as part of a response, outside legal counsel can advise on how to best present this information.
“15 Business Day” Response Timeframe and Potential Risks if Responses Are Inadequate
The FDA recommends, but does not require, submission of a written response within 15 business days. The draft guidance is explicit that the FDA will not delay regulatory actions—including issuing a warning letter—to review an untimely initial response. For complex observations that cannot be fully resolved within 15 business days, the FDA recommends that the initial response include a CAPA plan and a proposed timeline for completing substantive remediation.
After approximately 90 days, the FDA will provide a final inspection classification: no action indicated, voluntary action indicated, or official action indicated. If the FDA determines that significant regulatory violations exist and classifies the site as OAI, it may issue a warning letter. According to the Regulatory Procedures Manual (July 2024), “the agency position is that Warning Letters are issued only for violations of regulatory significance. Significant violations are those violations that may lead to enforcement action if not promptly and adequately corrected.” While the FDA’s guidance is not intended to guide firms submitting responses to warning letters, the proposed approach for assessing and responding to observations can be applied to warning letter responses as well.
If violations persist or present serious risks after the FDA has issued a warning letter, the FDA may pursue stronger enforcement actions, including import alerts, product seizures, injunctions, or criminal prosecution.
Conclusion
A well-written response will not, by itself, address findings of noncompliance. It represents an opportunity for the firm to communicate executive management’s commitments, describe its plans to address the FDA’s findings, and provide thoughtful, scientifically sound analysis and corrective actions. A timely, well‑structured, and substantive 483 response is the most effective lever a firm has to shape the FDA’s review, manage enforcement risk, and shorten the overall path to successful resolution of inspectional observations. The FDA’s draft guidance provides a clear roadmap for crafting 483 responses, and it puts industry on notice of the FDA’s expectations.
The FDA is accepting comments on the draft guidance until May 8, 2026.
If you have questions about the draft guidance or wish to submit written comments, we would be happy to assist you. In addition, clients should contact us about “Alston & Bird’s Best Practices for Writing 483 Responses,” a compilation of advice that we have provided to clients over the last two decades.
If you have any questions, or would like additional information, please contact one of the attorneys on our FDA: Compliance & Enforcement team.
You can subscribe to future advisories and other Alston & Bird publications by completing our publications subscription form.